Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced ...

Hopstem has already completed phase 1 testing of hNPC01 in China, with encouraging results, and says it has now reached ...

Currently in phase 2 trials, BB-031 is the first new mechanistic approach to ischemic stroke treatment in nearly 30 years.

A stroke patient at HonorHealth Research Institute is the first in Arizona to receive a new investigational treatment that ...

New nanomaterial passes the blood-brain barrier to reduce damaging inflammation after the most common form of stroke. When ...

Cellular death within the infarcted core occurs rapidly due to energy depletion, resulting in the release of DAMPs such as HMGB1, ATP, and HSPs. These DAMPs engage pattern recognition receptors, ...

Electromagnetic network-targeted field (ENTF) therapy, which targets specific connections in the brain, combined with physical therapy, significantly reduced disability in stroke survivors after 90 ...

Following the successful completion of the NHS national pilot in April 2025, the highly anticipated first results assessing CYP2C19 genetic testing to guide clopidogrel use in ischaemic stroke and TIA ...

As healthcare becomes more entrenched in the digital revolution, the need for an approved set of protocols for care delivery — clinical pathways — is becoming increasingly critical. Clinical pathways, ...

Hopstem Biotechnology Inc. (hereinafter referred to as "Hopstem"), a company dedicated to the development of induced ...